IAmThankful
2021-12-06
[What]
Biotechs are Getting Routed to Close the Year
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP,发表看法
APP内打开
发表看法
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":608488867,"tweetId":"608488867","gmtCreate":1638778076787,"gmtModify":1638778668668,"author":{"id":3572176137415007,"authorId":3572176137415007,"authorIdStr":"3572176137415007","name":"IAmThankful","avatar":"https://static.tigerbbs.com/70c6aad0b12d9421dbbed3a0b64ed057","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p><span>[What] </span><br></p></body></html>","htmlText":"<html><head></head><body><p><span>[What] </span><br></p></body></html>","text":"[What]","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/608488867","repostId":1190204658,"repostType":4,"repost":{"id":"1190204658","pubTimestamp":1638777403,"share":"https://www.laohu8.com/m/news/1190204658?lang=&edition=full","pubTime":"2021-12-06 15:56","market":"us","language":"en","title":"Biotechs are Getting Routed to Close the Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1190204658","media":"Motley Fool","summary":"The rapid development and production of Covid vaccines sent biotech stocks to new heights last year,","content":"<p>The rapid development and production of Covid vaccines sent biotech stocks to new heights last year, especially with shares in BioNTech and Moderna putting up numbers worthy of the NBA All-Star Game.</p>\n<p>With the new Omicron variant causing jitters, and demand for booster shots higher than ever, this year would seem poised to continue that streak. Instead, the biotech sector is ending 2021 in a brutal slump that's wiped billions off the investments of some of the industry's biggest hedge funds. There's still signs of life, though.</p>\n<p>Comeback City</p>\n<p>Even before the Covid pandemic, biotech funds were a shining star in the hedge-fund industry because of years of robust performance in the medical research sector. Perceptive Advisors founder Joseph Edelman bought a $70 million oceanfront mansion in California — the priciest in Orange County history —after his firm's funds rose 49% in 2019 and 31% in 2020.</p>\n<p>But now biotech's oceanfront is facing a perfect storm. Inflation in the US has pushed costs through the roof, the Omicron variant has led the FDA to prioritize Covid treatments over others, and some retail and institutional investors with a risky appetite are decamping for the wild world of crypto. It's made for some gruesome returns:</p>\n<ul>\n <li>The SPDR S&P Biotech ETF, the bellwether for the industry, lost 7% of its value in November, hit by all these compounding problems.</li>\n <li>Cancer immunotherapy firms Adaptimmune Therapeutics and Agenus each lost 18% of their value last month, and even COVID-19 vaccine developer Ocugen tanked by a shocking 46%, according to S&P Global Market Intelligence.</li>\n</ul>\n<p><b>Hedging Their Bets:</b>The main fund at Perceptive Advisors, which manages $9 billion, lost 30% this year through November, while an $18 billion healthcare fund at OrbiMed Partners lost 40%.</p>\n<p><b>Here's Hoping:</b>The current sell-off is seen by optimists as a blip — and previous declines have given way to bigger rallies. With new Covid-19 drugs on the way, revenues could boost in 2022 — SVB Leerink analysts predict American and European biopharmaceutical companies could have more than $500 billion on hand to deploy by late 2022.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biotechs are Getting Routed to Close the Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiotechs are Getting Routed to Close the Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-06 15:56 GMT+8 <a href=https://www.fool.com/investing/2021/12/05/biotechs-are-getting-routed-to-close-the-year/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The rapid development and production of Covid vaccines sent biotech stocks to new heights last year, especially with shares in BioNTech and Moderna putting up numbers worthy of the NBA All-Star Game.\n...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/05/biotechs-are-getting-routed-to-close-the-year/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AGEN":"艾吉纳斯公司","ADAP":"Adaptimmune Therapeutics plc","BNTX":"BioNTech SE","MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/12/05/biotechs-are-getting-routed-to-close-the-year/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190204658","content_text":"The rapid development and production of Covid vaccines sent biotech stocks to new heights last year, especially with shares in BioNTech and Moderna putting up numbers worthy of the NBA All-Star Game.\nWith the new Omicron variant causing jitters, and demand for booster shots higher than ever, this year would seem poised to continue that streak. Instead, the biotech sector is ending 2021 in a brutal slump that's wiped billions off the investments of some of the industry's biggest hedge funds. There's still signs of life, though.\nComeback City\nEven before the Covid pandemic, biotech funds were a shining star in the hedge-fund industry because of years of robust performance in the medical research sector. Perceptive Advisors founder Joseph Edelman bought a $70 million oceanfront mansion in California — the priciest in Orange County history —after his firm's funds rose 49% in 2019 and 31% in 2020.\nBut now biotech's oceanfront is facing a perfect storm. Inflation in the US has pushed costs through the roof, the Omicron variant has led the FDA to prioritize Covid treatments over others, and some retail and institutional investors with a risky appetite are decamping for the wild world of crypto. It's made for some gruesome returns:\n\nThe SPDR S&P Biotech ETF, the bellwether for the industry, lost 7% of its value in November, hit by all these compounding problems.\nCancer immunotherapy firms Adaptimmune Therapeutics and Agenus each lost 18% of their value last month, and even COVID-19 vaccine developer Ocugen tanked by a shocking 46%, according to S&P Global Market Intelligence.\n\nHedging Their Bets:The main fund at Perceptive Advisors, which manages $9 billion, lost 30% this year through November, while an $18 billion healthcare fund at OrbiMed Partners lost 40%.\nHere's Hoping:The current sell-off is seen by optimists as a blip — and previous declines have given way to bigger rallies. With new Covid-19 drugs on the way, revenues could boost in 2022 — SVB Leerink analysts predict American and European biopharmaceutical companies could have more than $500 billion on hand to deploy by late 2022.","news_type":1},"isVote":1,"tweetType":1,"viewCount":249,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":6,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/608488867"}
精彩评论